Back to Agenda
Session 5: Emerging Trends for Leveraging Patient Reported Outcomes (PROs) Inclusion in Labeling and CFL Communications
Session Chair(s)
Heta Zaveri, PharmD, MBA
Ad Promo Account Executive
Opus Regulatory Inc, United States
This session will provide a case study of an Exploratory PRO Inclusion in Oncology Labeling as well as discussion on leveraging CFL to communicate on PROs that may not be in labeling but are consistent with labeling. Finally, we will review recent enforcement relating to PRO promotion.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Identify emerging trends in the inclusion of Patient Reported Outcomes (PROs) in product labeling and corresponding CFL communications
- Discuss strategies for communicating PROs in CFL materials that align with labeling, and review recent enforcement actions related to PRO promotion
Speaker(s)
FDA’s Proactive Inclusion of PRO-CTCAE, an Exploratory Measure, in an Oncology Drug Label, Risk or Opportunity for Industry?
Denise Sanchez, JD, MA, MS
Opus Regulatory Inc., United States
Principal Consultant
Speaker
Nada A. Glavan, MPH
Eisai US, United States
Executive Director, Commercial Regulatory Affairs
Speake
Representative Invited
AbbVie, United States
Have an account?